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This paper addresses a family of issues surrounding the biological phenomenon of resistance and its rep-
resentation in realist ontologies. The treatments of resistance terms in various existing ontologies are
examined and found to be either overly narrow, internally inconsistent, or otherwise problematic. We
propose a more coherent characterization of resistance in terms of what we shall call blocking disposi-
tions, which are collections of mutually coordinated dispositions which are of such a sort that they cannot
undergo simultaneous realization within a single bearer. A deﬁnition of ‘protective resistance’ is pro-
posed for use in the Infectious Disease Ontology (IDO) and we show how this deﬁnition can be used to
characterize the antibiotic resistance in Methicillin-Resistant Staphylococcus aureus (MRSA). The ontolog-
ical relations between entities in our MRSA case study are used alongside a series of logical inference
rules to illustrate logical reasoning about resistance. A description logic representation of blocking dispo-
sitions is also provided. We demonstrate that our characterization of resistance is sufﬁciently general to
cover two other cases of resistance in the infectious disease domain involving HIV and malaria.
 2010 Elsevier Inc. All rights reserved.1. Introduction: IDO, SaIDO, and MRSA IDO is itself an extension of the Basic Formal Ontology (BFO)11The phenomenon of resistance is an important feature of bio-
logical reality, encompassing diverse phenomena such as: the
resistance of an individual to speciﬁc diseases, the herd immunity
of an organism population to certain populations of infectious
organisms, the resistance of disorders (for example, tumors) to
speciﬁc treatments, and the resistance of certain pathogens to cer-
tain drugs. Treatment decisions and public health policies often
hinge on correctly identifying types of resistance [1]. As such, resis-
tance is a phenomenon that needs to be captured in biomedical
ontologies in a consistent, coherent, and sufﬁciently general way.
Our primary goal in this communication is to characterize resis-
tance in the infectious disease domain. The Infectious Disease
Ontology (IDO) consortium is developing a set of interoperable
ontologies that together are intended to provide progressively
expanding coverage of the infectious disease domain. Central to
this set is the IDO Core ontology, which provides a representation
of entities, drawn from both the biomedical and the clinical do-
mains, that are relevant to infectious diseases in general. Do-
main-speciﬁc extensions (e.g., pathogen-speciﬁc extensions) of
the IDO Core complete the set by providing ontology coverage
for the types of entities relevant to speciﬁc sub-domains of the
infectious disease ﬁeld.ll rights reserved.
. Goldfain), phismith@buffa-and links to other ontologies constructed according to the principles
of the Open Biomedical Ontologies (OBO) Foundry.2 IDO takes its
treatment of disease from the Ontology for General Medical Science
(OGMS),3 which distinguishes between:
1. a disease,
2. its diagnosis,
3. its signs and symptoms,
4. its realization in the series of processes we call a disease course,
and
5. the underlying disorder(s) on the side of the patient in which
the disease is rooted [2].
We mention these distinctions here because the conﬂation of enti-
ties of any of types listed can lead to confusion and error in reason-
ing about complex biomedical phenomena in general and about
resistant entities in particular.
The Staphylococcus aureus Infectious Disease Ontology (SaIDO)
is an extension of IDO concerning Staph aureus (Sa) infection. Sa
can be partitioned into two subtypes4: Methicillin-Susceptible Sa
(MSSa) and Methicillin-Resistant Sa (MRSA). The latter subtype is ahttp://www.ifomis.org/bfo
2 http://www.obofoundry.org/
3 http://code.google.com/p/ogms/
4 Further reﬁnement of SaIDO may involve the creation of MRSAIDO and MSSaIDO
sub-ontologies which overlap in SaIDO.
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(and other b-lactam antibiotics). Due to its rapid evolution in the
face of antibiotic selective pressures, MRSA has become the paradigm
of resistance (a so-called ‘‘superbug”), and has drawn signiﬁcant
attention from NIAID/NIH,5 CDC,6 and biomedical researchers
throughout the developed world.
Subtypes of Sa can also be speciﬁed by assigning bacterial
strains to clonal complexes based on genotypic differences. Vari-
ants can differ in their degree of resistance and in the types of drug
to which they are resistant, forming a continuum, in terms of
which Sa can be (and is) categorized. This provides one powerful
reason to produce an ontologically correct representation of resis-
tance in the infectious disease domain, and there are several
others:
1. A classiﬁcation of Sa that would allow inference of resistance
proﬁle.
2. IT tools for monitoring the number of infections from resistant
strains observed in each hospital, thus allowing for: early detec-
tion of increases, anticipation of outbreaks, and tracking the
spread of resistant strains.
3. Tools to guide in the writing of prescriptions.
In this paper, we consider the issues arising from the represen-
tation of resistance in realist ontologies and speciﬁcally, in IDO. In
Section 2 we list a set of desirable features for such a representa-
tion. In Section 3 we survey some problems with resistance repre-
sentations in other ontologies and devise a deﬁnition of ‘protective
resistance’ for IDO with our desiderata in mind. We then focus our
attention on the antibiotic resistance of MRSA to methicillin as a
detailed case-study in Section 4. We characterize our representa-
tion in terms of blocking dispositions (Section 5), and show how
our deﬁnition is general enough to apply to other important cases
of resistance in the infectious disease domain (Section 6).2. Desiderata for an ontological representation of resistance
Before reviewing how ‘resistance’ is deﬁned in other ontologies
and providing our own deﬁnition, it will be useful to list the desid-
erata for a good deﬁnition. We implicitly append to this list the
desiderata for all good ontological deﬁnitions, such as non-circu-
larity, Aristotelian form, and providing necessary and sufﬁcient
conditions.2.1. Positivity principle
An important principle for realist ontology development is to
avoid as far as possible the use of negative differentia (e.g., ‘non-
physical’, ‘not part of the heart’, ‘not otherwise speciﬁed’) in formu-
lating deﬁnitions. This ‘‘positivity design principle” enforces the
use of terms which capture information about the entities repre-
sented in the ontology rather than information about the state of
our knowledge at some given time [3].
At some level, however, resistance seems to require a negative
aspect for its description. After all, a continuant is resistant pre-
cisely when something does not happen. John’s resistance to mar-
riage entails a host of processes that do not happen (for example,
John does not buy an engagement ring, does not get a marriage li-
cense, and so forth). In the case of MRSA, resistance to methicillin
entails that a process of cell wall formation is not interfered with.
The key is that the implicit negativity of resistance is only a seman-5 http://www3.niaid.nih.gov/topics/antimicrobialResistance/Research/
niaidsRole.htm
6 http://www.cdc.gov/ncidod/dhqp/ar_mrsa_CDCactions.htmltic feature of the description at some level. The biological phenom-
enon of resistance is manifested at various levels of biological
reality: genes, cells and their parts, organs, organisms, and popula-
tions. Negative descriptions at a macroscale here mask the positive
and active aspects of resistance at the microscale. A comprehensive
ontological treatment must, accordingly, consider resistance at dif-
ferent levels of granularity.
In BFO-based ontologies, the lacks relation can be used to cap-
ture negative ﬁndings at one scale of biological description while
avoiding the problems of using negative predicates or characteris-
tics [4]. In describing resistance, we will need to say that indepen-
dent continuants of a certain type do not exhibit a dependent
continuant of a certain type. As we will see below, this amounts
to an independent continuant lacking a certain disposition.
2.2. Doing justice to multiple disciplinary perspectives
Along with the various granularities at which we want to talk
about resistance, we also must acknowledge that resistance is re-
ferred to by several disciplines: epidemiologists describe the
spread of resistance in a population, the medical community
speaks of patient resistance to disease and of pathogen resistance
to drugs. Geneticists make reference to the genes that confer resis-
tance when certain alleles are present. Incrementally, the IDO suite
of ontologies must capture all of these discipline-speciﬁc aspects of
resistance and the relations between them.
2.3. Nonproliferation of new relations and terms
The terms used in our representation will be derived from IDO,
the Gene Ontology (GO), and the Protein Ontology (PRO). The rela-
tions used are drawn from the OBO Relation Ontology (RO) and its
extensions.7 Naïvely, we could introduce a new relation resistant_to
and use it to describe every instance of a resistance phenomenon.
However, this would hide the complexity of the mechanisms of
resistance working at smaller scales and eliminate many important
inferences about resistance. Also, it is important to avoid a prolifer-
ation of relations in the OBO Foundry, since restriction to a small set
of relations promotes reuse and interoperability of the constituent
ontologies.
2.4. Explanatory value
An assertion of resistance of X to Y should not be tautological or
otherwise trivial. Appeals to resistance should be explanatory,
which means that resistance itself should be represented in such
a way as to provide some explanation of why certain processes un-
fold the way they do. The assertion of resistance of X to Y should be
a useful response to a query; it should be a proposition on which to
base further reasoning [5].
2.5. Formalizability
Finally, the deﬁnition should be expressible using the ontologi-
cal tools of the trade. IDO supports machine-readable representa-
tions using both OWL and OBO formats. For use in OWL,
resistance should be expressible using description logic
restrictions.
In summary, we have ﬁve desiderata for a representation of
resistance:
1. Positivity principle: What is the active mechanism producing
resistance and what is the associated physical basis?7 http://www.obofoundry.org/ro/
8 For more on BFO realizable entities, see [6].
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between what has resistance and what confers resistance?
3. Nonproliferation of new relations and terms: What OBO
Foundry relations and terms can be utilized?
4. Explanatory value: Is resistance characterized so as to be a
suitable result of an inference or a response to a query?
5. Formalizability: Can resistance be inferred from a formal rep-
resentation of the relevant domain using ﬁrst order logic? Can
it be expressed using description logic?
3. Resistance in existing ontologies
We surveyed the treatment of resistance in existing ontologies.
3.1. Gene Ontology (GO)
The treatment of resistance is, strictly speaking, outside the
scope of the GO, as resistance is not a biological process, molecular
function, or cellular component. Within the sub-ontology of bio-
logical processes, however, GO contains the term ‘response to
drug’, with putative synonyms ‘drug resistance’ and ‘drug suscep-
tibility/resistance’ (although ‘drug resistance’ has been obsoleted
from GO, it still remains a synonym for the term ‘response to drug’)
[GO:0042493] Response to Drug: A change in state or activity of
a cell or an organism (in terms of movement, secretion, enzyme
production, gene expression, etc.) as a result of a drug stimulus.
It is of course incorrect to view the narrower term ‘drug resistance’
as a synonym of the broader term ‘response to drug’. Drug resis-
tance arises spontaneously as the result of genetic diversiﬁcation.
The presence of the drug provides an environment in which those
individuals (cells or viral particles) that have the resistance confer-
ring gene or mutation have a ﬁtness advantage, thus they outcom-
pete the susceptible individuals. The resistance is not a direct
response to the drug stimulus, although the manifestation of resis-
tance may be a consequence of prior exposure to the drug. A re-
sponse to a drug is a process, whereas resistance is a continuant,
and thus ‘response to drug’ should not be a synonym of ‘drug resis-
tance’. The GO deﬁnition deﬁnes resistance at the scale of cell or
organism, but would not apply to molecules or populations. Finally,
the deﬁnition seems to hinge on a ‘change in state’, but cells which
do not change state are manifesting a ‘response to a drug’ just as
much as are those which do, and in fact, resistant cells may not
change state at all.
3.2. NCI Thesaurus
The NCI Thesaurus has the following entry for ‘resistance’:
[C19391] Resistance: Natural or acquired mechanisms, func-
tions, activities, or processes exhibited by an organism to main-
tain immunity to, or to resist the effects of, an antagonistic
agent, e.g., pathogenic microorganism, toxin, drug.
The primary problems with this treatment of resistance are that:
(i) the deﬁnition is circular, since it uses ‘resist’ in deﬁning
‘resistance’; and
(ii) the deﬁnition applies at the scale of the organism, ignoring
the scale of the cell, molecule, or population;
(iii) the term ‘resistance’ is a child of ‘‘resistance process”, mak-
ing resistance a process and excluding many types of resis-
tance, because the deﬁnition of ‘resistance process’ is
biased towards multicellular organism resistance mediated
by host defense mechanisms.3.3. SNOMED-CT
SNOMED-CT contains the entry ‘drug resistance (disorder)’ with
two deﬁning relationships:
Drug Resistance Is a Drug-Related Disorder
Drug Resistance has Causative Agent (Attribute)
Drug or Medicament.
The former, which assigns to ‘drug resistance’ the parent term
‘drug-related disorder’, is formulated from the perspective of the
patient. From the perspective of the pathogen or tumor, in contrast,
drug resistance is not a disorder, but rather a beneﬁt. That
SNOMED adopts this patient-based perspective is not surprising.
SNOMED, speciﬁes that drug resistance is caused by a drug, but
drug resistance is caused by the presence of a gene or mutation.
It is only the manifestation of such resistance that results from
the presence of the drug. Finally, as with other terms in SNOMED,
only necessary but not sufﬁcient conditions for drug resistance are
provided. Good deﬁnitions should spell out both.
3.4. Infectious Disease Ontology (IDO)
In IDO, resistance is represented as a BFO disposition
Disposition¼def A disposition is a realizable entity8 which is
such that, if it ceases to exist, then its bearer is physically chan-
ged, and whose realization occurs in virtue of the bearer’s phys-
ical make-up when this bearer is in some special circumstances.
In English, the word ‘resistance’ is polysemous and can be used to
refer to either a disposition or a quality (i.e., a categorical property).
When referring to a quality, ‘resistance’ is roughly synonymous
with ‘low susceptibility’. If we think of degree of susceptibility as
a continuum, then the quality of resistance is the region of this con-
tinuum beneath a certain threshold. As a disposition, resistance is
possessed in virtue of the internal physical arrangement of its
bearer, is not always manifested when borne, and is realized in ac-
tive processes at some physical scale. It is this realizable sense of
‘resistance’ that we want to represent: resistance is the capability
(and in some cases the function) to resist under certain conditions.
IDO includes the term ‘protective resistance’, the deﬁnition of
which attempts to address some of the problems described above:
Protective resistance is a disposition that inheres in a material
entity (x) by virtue of the fact that the entity has a part (e.g., a
gene product), which itself has a disposition 1) to ensure a
physiologic response of a certain degree to an entity of type Y
with the capability to damage x, or 2) to prevent the completion
of some process caused by an entity of type Y with the capabil-
ity to damage x. The realization of the disposition protects x
from or mitigates the damaging effects of Y. The protective
resistance disposition is realized in a biological process.
Here we write lowercase x to indicate an instance, and capital Y to
indicate a type.
4. Towards a more robust ontological treatment of protective
resistance
To better understand the representational demands posed by
resistance (and to expose the problems raised by this and similar
phenomena from an ontological point of view), it will be useful
to go through a detailed example. We choose drug resistance for
a single combination of pathogen, antibiotic, and resistance-mech-
anism types. In this section we sketch the outlines of a formal rep-
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Fig. 1. A graph representation of a subset of the MRSa domain triples.
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PBP2a, a penicillin-binding protein (PBP) and a product of the gene
mecA. Both methicillin and penicillin are b-lactam antibiotics and,
for the purposes of our formalization, a PBP can be considered to be
a methicillin binding protein. Chambers gives a concise description
of the form of resistance involved:
[M]ethicillin resistance in staphylococci is due to expression of
PBP2a, a novel, low-afﬁnity PBP for which there is no homo-
logue in methicillin-susceptible strains [7].
We formalize this information as a set of triples expressing the rel-
evant ontological relationships. We also include a series of inference
rules that would lead a logic-driven reasoner to deduce from the tri-
ples that MRSA is resistant to methicillin. Such inference rules will
one day be used by automated reasoners to compute antibiotic
resistance from logical formalizations of such domains. Using ontol-
ogies as predictive tools will help to guide treatment decisions and
support automated drug discovery.
A faithful representation of the MRSA domain requires at least
the following components (where is_a and has_part are used for
relations between both continuant and occurrent universals):
1. bacterium is_a organism
2. MRSA is_a bacterium
3. synthesis_of_peptidoglycan is_a process and has_partici-
pant Penicillin_Binding_Protein (PBP)9
4. PBP has_function_realized_as_process synthesis_of_
peptidoglycan
5. Bacterial_cell_wall is_location_of PBP
6. Canonically, synthesis_of_peptidoglycan results_in_devel-
opment_of bacterial_cell_wall
7. formation_of_bacterial_cell_wall is_a process
8. PBP2a is_a PBP
9. methicillin_PBP_binding_process is_a binding process that
has_participants methicillin and PBP
10. afﬁnity_to_methicillin disposition_of some PBP to undergo
a methicillin_PBP_binding_process that is realized in the
presence of a methicillin9 Here we chain together two triples for brevity.11. methicillin_PBP_binding_process negatively_regulates syn-
thesis_of_peptidoglycan
12. PBP2a lacks afﬁnity_to_methicillin
13. mecA is_a gene
14. MRSA has_part mecA
15. mecA participates_in PBP2a_production
16. PBP2a_production results_in_formation_of PBP2a
A subset of these triples is depicted graphically in Fig. 1. Resistance
to methicillin should be inferred from such representations in a
logical manner. Such inferencing should be explanatory: it should
tell us why MRSA bears such resistance.
These triples will be used along with several rules of inference
and derived facts (labeled IRn and Dn respectively in what follows).
For readability, all variables are italicized and initial universal
quantiﬁer symbols are suppressed. First, we specify that is_a and
has_part (for both continuants and occurrents) are transitive,
allowing us to derive some basic taxonomic facts about the
domain:
(IR1) x is_a y ^ y is_a z! x is_a z
(IR2) x has_part y ^ y has_part z! x has_part z
(D1) MRSA is_a organism
The parts of an organism are the products of the organism’s
expressed genes, and these products are located in the appropriate
places:
(IR3) o is_a organism ^ g is_a gene ^ o has_part g^
g participates_in proc ^ proc results_in_formation_of
prod
^o has_part locp ^ locp is_location_of prod!
o has_part prod located_in locp
(D2) MRSA has_part PBP2a located_in bacterial cell wall
The inference rule (IR3) makes a few simplifying assumptions.
Since not all genes are expressed, we are only modeling the situa-
tion in which g is an expressed gene. We also assume that the pro-
cess proc leading to prod is active, and that the single gene g
participates in proc (rather than a set of genes).
A. Goldfain et al. / Journal of Biomedical Informatics 44 (2011) 35–41 39If a continuant lacks a disposition to undergo a process in some
situation, and that process negatively regulates a second process
which has the continuant as a participant, then the continuant par-
ticipates in the second process in that situation:
(IR4) p lacks disposition to undergo proc1 realized in situation s ^
proc1 negatively_regulates proc2 ^ proc2 has_participant
p!
In situation s; p participates_in proc2
(D3) In the presence of methicillin
PBP2a participates_in synthesis of peptidoglycan
This lack of a disposition (i.e., the afﬁnity to methicillin) has a cat-
egorical basis in the fact that methicillin binds to PBPs and pre-
vents them from carrying out their function. However, PBP2a
lacks this afﬁnity, so the presence of methicillin does not prevent
the essential subprocesses of cell-wall construction in MRSA.
If an organism has a continuant as a part and that part partici-
pates in a process in some situation, then the process unfolds in the
organism in that situation.
(IR5) In situation s; p1 participates_in proc ^
p1 located_in p2 ^ o has_part
p2 !
proc unfolds_in o in situation s
(D4) synthesis of peptidoglycan unfolds_in MRSA
in the presence of methicillin
Finally, if a process unfolds in an organism in some situation and
the process results in the development of a continuant which
(canonically) is a part of the organism, then the organism has the
continuant as a part in that situation.
(IR6) In situation s; proc unfolds_in o^
Canonically; proc results_in_development_of
p !10 This section is adapted from a conference submission by the authors to Formal
Ontology in Information Systems [10].
11 Note that since we are dealing with the impossibility of co-occurrence, we could
also take the disposition to bind to PBP as a blocking disposition for the disposition top part_of oin situation s
(D5) Bacterial cell wall part_of MRSA in the presence of methicillin
The canonical cell wall is a rigid conﬁguration of peptidoglycan.
The canonical cell wall is a healthy one for MRSA. The assertion
(D5) captures the active, and thus positive, microphysical side of
the resistance coin.
However the chain of reasoning here presents a puzzle. What
does the lack of a disposition in (IR4) amount to? Consider the fol-
lowing pair:
(A) Continuant C lacks disposition D to undergo process P in sit-
uation S.
(B) Continuant C undergoes P in a situation S.
Both (A) and (B) can be true at the same time. In fact the conjunc-
tion of (A) and (B) implies that (B) happens for a non-dispositional
reason (i.e., (B) is not, in the corresponding case, a manifestation of
the disposition D). Even if John lacks the disposition to feel hungry
when in the presence of sushi, he may still feel hungry in such a
situation because he has been fasting for three days. We need a
way to express the fact that PBP2a necessarily lacks afﬁnity to
methicillin, and that this is what allows for the relevant cell-wall
formation to take place. In order to frame the necessary lack as a
positive and explanatory account, we will need the framework of
blocking dispositions described below.
An important aspect of the chain of reasoning is the use of can-
onicity in domain triple 6:
Canonically, synthesis_of_peptidoglycan results_in_develop-
ment_of bacterial_cell_wall.Here ‘canonically . . .’ works to specify a baseline of what is held to
be true according to some canonical ontological reference (e.g., the
anatomy of a model organism). Although this construction resem-
bles the syntax of the modal operator ‘Necessarily,. . .’, it does not
yield a substantial ontological claim, but rather just says what is
true relative to the particular reference. This form of reasoning with
canonicity is consistent with its use in anatomical reasoning [8,9].
In our case, we assume that a reference ontology of the cell speciﬁes
that synthesis of peptidoglycan results in the development of a cell
wall. Such assumptions are axiomatic for IDO because they are be-
yond the scope of the core ontology and they provide a useful con-
straint for a reasoner. The chain of reasoning relies on such axioms
and we expect that they will grow in number to accommodate the
reasoning needs of IDO extensions.5. Resistance as blocking disposition10
An explanatory positive account for PBP2a lacking an afﬁnity to
methicillin can be given if we consider what prevents the manifes-
tation of this disposition. Often what prevents the realization of a
disposition is the manifestation of another disposition. We call
the latter a blocking disposition and the former a blocked disposition.
Dispositions are often said to manifest given certain background
conditions, contexts, or circumstances [11,12]. Blocking disposi-
tions emphasize the ontological interactions in the background.
In general, if D1 is a disposition and D2 is a blocking disposition
for D1, then it must be the case that the realization of D2 prevents
the realization of D1. A blocking disposition might be understood in
different ways:
1. Incompatible occurrents: The realization of D1 and the realiza-
tion of D2 are somehow incompatible occurrents, meaning
either that they cannot co-occur or that one negatively regu-
lates the other.
2. Incompatible qualities: The realization of D2 results in a qual-
ity of a continuant that is incompatible with the quality of the
same continuant that would have resulted from the realization
of D1. That is, we have two qualities that cannot be simulta-
neously exhibited (e.g., a square circular object).
By giving resistance a positive characterization, in which we de-
scribe what dispositions are actively realized, resistance can play a
more explanatory role. We can describe this resistance without ref-
erence to blocking dispositions by noting the lack of afﬁnity to
methicillin (a disposition) in the relevant portion of the penicil-
lin-binding protein of MRSA (PBP2a). As an explanation of why
MRSA is resistant, however, invoking the lack of afﬁnity to methi-
cillin seems to be begging the question; MRSA is resistant to meth-
icillin because one of its parts lacks an afﬁnity for it. The same
situation can be described in a positive (active) way by considering
the disposition of PBP2a to synthesize peptidoglycan (an essential
component of the bacterial cell wall) as a blocking disposition for
the disposition of methicillin to bind to penicillin-binding pro-
teins.11 In this way, protective resistance can be redescribed as an
active response to methicillin.
In this situation, we can argue for incompatible occurrents: the
process of cell-wall construction (as a realization of the typical dis-
position of PBP) is incompatible with the process of methicillin
binding (which is the realization of afﬁnity to methicillin that
PBP2a lacks). We could also argue for incompatible qualities: forsynthesize peptidoglycan.
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incompatible with being bound to peptidoglycan peptide subunits.
As a result, the molecular structure of a well-formed bacterial cell
wall (i.e., a peptidoglycan lattice) is incompatible with the molec-
ular structure of a compound sufﬁciently bound to methicillin.
Cell-wall construction is something a bacterium will participate
in when no methicillin is present. In order to see this canonical
process as an active response, we need the machinery of blocking
dispositions. Protective resistance to methicillin is exhibited by
MRSA in the process of cell-wall construction by blocking the dis-
position of methicillin to bind to PBP.
In order for a theory of blocking dispositions to be useful in
computational inference, it should be expressible in a formal lan-
guage. For this task, we prefer description logic because: (1) it is
the logic underlying OWL-DL, and (2) description logic is relatively
inexpressive, so if we can capture blocking dispositions in descrip-
tion logic, we should be able to represent blocking dispositions in a
more expressive formalism. It is easiest to formulate a blocking
disposition as a description logic restriction by using the RO_Pro-
posed relation negatively_regulatesD2 blocking disposition of D1  9realized by
ð9negatively regulates 9realizes D1 u 9realizes D2ÞBut we may also describe the inability for D1 and D2 to co-occur
using a cardinality restriction12:9realizes D1 u 9realizes D2 u 9occurs at T ¼ ;Description logic does not provide schema variables in the way we
have used them in D2 blocking disposition of D1, so each such dispo-
sition must be ﬂeshed out in concrete terms by the IDO extension
ontologies.
Such an analysis is not without its problems. One minor concern
is that calling something a blocking disposition may be considered
too perspectival, biasing the ontological term towards D1 being
blocked by rather than blocking D2. A more serious problem is
how can we empirically distinguish between something not hap-
pening to a speciﬁc continuant as the result of (1) an external
blocking disposition or (2) as the result of its own internal makeup.
A further worry involves the identity criteria for blocking dispo-
sitions. Storm-resistant walls on a particular house are most likely
also lemonade-resistant as well, but in virtue of the same underly-
ing structure (i.e., categorical properties). So is the particular lem-
onade resistance inhering in those walls identical to the particular
water resistance inhering in those walls? It seems counterintuitive
to say so, but if we say these are not identical are we not opening
the door to a combinatorial explosion of resistance dispositions?
Similarly, penicillin-binding protein has an afﬁnity to penicillin
(as its name suggests) which is conferred by the same qualities
that yield methicillin resistance, but we do not want to say that
these forms of resistance are identical because some staph aureus
may be susceptible to methicillin but resistant to penicillin. The
standard answer to such worries from the realist ontology camp
is that terms are included in an ontology in reﬂection not of what
is combinatorially possible but rather of the actual needs of biolo-
gists who are describing real biological phenomena. Whether dis-
positions referred to by such terms are or are not identical will
need to be decided on a case-by-case basis, but such a decision is
then not in principle more problematic for dispositions than for
entities of other sorts.12 By our notational convention, ; denotes a cardinality of 0.6. Other examples
The blocking disposition characterization presented above can
be applied to different types of resistance. In this section, we pres-
ent two examples involving infectious disease: (1) CCR5 mutation
confers protective resistance against certain strains of HIV, and (2)
the sickle cell trait confers protective resistance against malaria.
Like the case of MRSA, we will see that the simple macroscale char-
acterization of resistance gives way to a network of related entities
at the microscale.6.1. CCR5-D32 and HIV
Certain strains of HIV have a disposition to bind to CCR5 (com-
plemented, like a lock and key, with the disposition of CCR5 to bind
to HIV) and thus enter cells. CCR5-D32 is a deletion mutation of the
CCR5 gene resulting in cells which lack a functioning CCR5 receptor
on their surfaces [13]. Note that HIV does not lose the disposition
to bind to CCR5, the disposition simply goes unmanifested.
Similar to thecaseof antibiotic resistance inMRSA,wearedealing
here with a part of an organism lacking a continuant; in this case,
however, what ismissing is an independent continuant (i.e., a portion
of canonical CCR5). To characterize something as lacking a disposi-
tion is to provide a negative characterization that stands in need of
further explanation — as contrasted with characterizing something
as lacking a part, which is a positive characterization. The fact that
a cell lacks CCR5 receptors on its surface is a quality of the cell.
This case of resistance to HIV is covered by the clause of the IDO
deﬁnition for protective resistance in which the process caused by
a potentially damaging entity is prevented from completing. In
terms of blocking dispositions, this situation can be described in
terms of incompatible qualities. If d1 is the disposition of HIV to
bind to a CCR5 molecule, and d2 is the disposition of individuals
with the CCR5-D32 mutation to develop cells without CCR5 on
their surface, then we have d2 blocking d1 because the realization
of both would require the same continuant (i.e., a T cell or macro-
phage) to exhibit incompatible qualities by simultaneously having
and lacking CCR5 on its surface.6.2. The sickle-cell trait and malaria
There are many hypothesized mechanisms by which the sickle
cell hemoglobin gene (HbS) confers resistance to Plasmodium falci-
parum, one of the infectious organisms that causes malaria. One
such mechanism is through the impact of HbS on red blood cell
hydration and density [14]. In individuals with HbS, red blood cells
are disposed to dehydration and a consequent increase in density.
Plasmodium falciparum merozoites have a disposition to spread
through host red blood cells. This spreading process consists of
four subprocesses: plasmodium replication inside a single red
blood cell, red blood cell lysis, release of plasmodium merozoites
from the lysed cell, and entry of released merozoites into a new
red blood cell. Merozoite invasion of dense, dehydrated red blood
cells is reduced. Thus, an essential subprocess of the spread of plas-
modium in the host is reduced (the process is negatively regu-
lated), thus conferring protective resistance against malaria.
Using blocking dispositions, we can again characterize this sit-
uation in terms of incompatible qualities. If d1 is the disposition
of certain red blood cells to become dehydrated, and d2 is the dis-
position of plasmodium to spread through red blood cells, then the
realization of d1 results in a hydration quality inhering in the red
blood cells, thereby negatively regulating the realization of d2,
which requires hydrated red blood cells. The qualities are incom-
patible because a red blood cell cannot simultaneously be hydrated
and dehydrated.
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If we take resistance to be a speciﬁcally dependant continuant
that inheres in an independent continuant, then we must still an-
swer some mereological questions: Is the resistance of the relevant
portion of PBP2a (i.e., of a part) identical to the resistance of the
cell (i.e., of the including whole)? Furthermore, is cell resistance
identical to the resistance of a portion of tissue in which the cell re-
sides or the containing host organism or, for that matter, of the
containing population? The ontology of resistance must address
which scales of biological reality resistant continuants occupy,
and the identity of resistance across scales.
We can begin to address this question for our case study by con-
sidering a biochemical explanation of whymethicillin does not bind
to PBP2a. Indeed, a structural explanation involving the biochemis-
tryof PBP2aandb-lactamantibiotics is known [15]. This explanation
involves facts about chemical structure of the peptide links between
glycan chains in peptidoglycan and the chemical structure of meth-
icillin. The conﬁguration of such structures, in turn, hinges on facts
about how proteins fold and the basic chemical rules governing
how bonds between carbon, oxygen, hydrogen, and nitrogen form.
There are several ontological resources to represent such chemical
structures (e.g., ChEBI13), but at this molecular scale we are only rea-
soning about structures (qualities in BFO) that are the physical basis
for the resistance disposition, not about the disposition itself. Simply
put, the resistance of MRSA to methicillin is not identical to an aggre-
gate of chemical structures, but it is borne in virtue of such structures.
Importantly, we also want to be able to talk about resistance at the
physiological andpopulation levelswhenwecan talk about the conse-
quences at those levels of the chemical structures that confer resis-
tance, and also when we have incomplete microscale information
about such structures. This is another reason an ontology like IDO
should provide terms for the entities existing at both scales.
A related issue that should be addressed at different scales of bio-
logical reality is the way in which facts at each scale are used to ex-
plain the phenomenon of resistance. At the genetic scale, MRSA
havingmecA andMSSa lackingmecA are explanatory. At the cellular
level, inference (D5) is explanatory. To help link scales of biological
reality, the proposed IDO deﬁnition for protective resistance given
above speciﬁes that a material entity is resistant in virtue of one of
its parts (or one of its members in the case of a population), but fur-
therworkof speciﬁcationof partsmustbedone in the respective IDO
extension ontologies in order for us to be able to exploit multiscale
reasoning. As stated above, structural facts (BFO qualities) alone
may not be explanatory because they do not include information
of how entities with different structures interact. Interactions (BFO
processes) alone are not explanatory because they do not include
information about what it is in the interacting participants that en-
ables these interactions to happen. Dispositions are the explanatory
glue between structures and interactions.8. Conclusion
We have attempted to provide a deﬁnition of protective resis-
tance that is general enough to cover the varied types of resistance
in the infectious disease domain, speciﬁes the components of resis-
tance at multiple scales and across ontological types (along with
how those components relate to each other), and is capable of being
extended to cover speciﬁc forms of resistance in this domain. We
have seen that resistance is an important multiscale phenomenon,
oftenwith a one-to-many relationshipbetweena resistant organism
and the underlyingmechanisms of resistance. Several desiderata for
an ontological representationwere found lacking in existing ontolo-13 http://www.ebi.ac.uk/chebi/gies. Our preliminary formal representation of resistance honors a
positivity design principle, by providing an analysis for its negative
characterizations (e.g., the lack of a disposition). It also conforms
to a principle of non-proliferation of relations by reusing existing
RO relations. Using the formalism of blocking dispositions, we are
able to analyze the multiscale interactions that give rise to resis-
tance. Such an analysis adds explanatory value to an inferred fact
about the resistance of MRSA to methicillin. Certain assumptions
of canonicity are needed, namely the assumptions that all entities
(e.g., anatomical and cellular component entities) are canonical
and that no exogenous factors are present unless explicitly stated
(e.g., methicillin). This canonical representation of resistance is,
however, able to cover several different types of resistance. Our def-
inition of protective resistance was shown to be sufﬁciently general
to cover resistance phenomena involving malaria and HIV. In these
cases, as in the case of MRSA, we demonstrated how resistance in-
volves the prevention of the completion of an essential subprocess
by the potentially harmful entity.
Some issues remain (e.g., in providing a systematic account for
the lack of a disposition that overcomes some of the issues we have
identiﬁed), but we are conﬁdent that further study of resistance
will have great beneﬁts for biomedical ontologies. For example,
this work might be extended by considering the logical rules nec-
essary to infer novel forms of resistance from a known resistance
type, potentially across related drugs and species.
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